| High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin T Tanno, NV Bhanu, PA Oneal, SH Goh, P Staker, YT Lee, JW Moroney, ... Nature medicine 13 (9), 1096-1101, 2007 | 1035 | 2007 |
| Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors JJ Luke, JM Lemons, TG Karrison, SP Pitroda, JM Melotek, Y Zha, ... Journal of Clinical Oncology 36 (16), 1611, 2018 | 515 | 2018 |
| Current recommendations and recent progress in endometrial cancer RA Brooks, GF Fleming, RR Lastra, NK Lee, JW Moroney, CH Son, ... CA: a cancer journal for clinicians 69 (4), 258-279, 2019 | 478 | 2019 |
| PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors F Janku, AM Tsimberidou, I Garrido-Laguna, X Wang, R Luthra, DS Hong, ... Molecular cancer therapeutics 10 (3), 558-565, 2011 | 429 | 2011 |
| Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma PA Konstantinopoulos, S Waggoner, GA Vidal, M Mita, JW Moroney, ... JAMA oncology 5 (8), 1141-1149, 2019 | 411 | 2019 |
| Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and … J Moroney, S Fu, S Moulder, G Falchook, T Helgason, C Levenback, ... Clinical cancer research 18 (20), 5796-5805, 2012 | 99 | 2012 |
| Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast … S Moulder, J Moroney, T Helgason, J Wheler, D Booser, C Albarracin, ... Journal of Clinical Oncology 29 (19), e572-e575, 2011 | 77 | 2011 |
| Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer S Moulder, T Helgason, F Janku, J Wheler, J Moroney, D Booser, ... Annals of Oncology 26 (7), 1346-1352, 2015 | 64 | 2015 |
| A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies JW Moroney, MP Schlumbrecht, T Helgason, RL Coleman, S Moulder, ... Clinical cancer research 17 (21), 6840-6846, 2011 | 59 | 2011 |
| Fetal hemoglobin silencing in humans PA Oneal, NM Gantt, JD Schwartz, NV Bhanu, YT Lee, JW Moroney, ... Blood 108 (6), 2081-2086, 2006 | 54 | 2006 |
| Improved survival associated with local tumor response following multisite radiotherapy and pembrolizumab: secondary analysis of a phase I trial JJ Luke, BE Onderdonk, SR Bhave, T Karrison, JM Lemons, P Chang, ... Clinical Cancer Research 26 (24), 6437-6444, 2020 | 44 | 2020 |
| Aflibercept in epithelial ovarian carcinoma JW Moroney, AK Sood, RL Coleman Future Oncology 5 (5), 591-600, 2009 | 44 | 2009 |
| Phase III MIRASOL (GOG 3045/ENGOT-Ov55) study: mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian … KN Moore, A Angelergues, GE Konecny, S Banerjee, S Pignata, ... J Clin Oncol 41, abstrLBA5507, 2023 | 37 | 2023 |
| Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer S Chen, P Xie, M Cowan, H Huang, H Cardenas, R Keathley, EJ Tanner, ... The Journal of Clinical Investigation 132 (14), 2022 | 36 | 2022 |
| Safety and clinical activity of atezolizumab plus bevacizumab in patients with ovarian cancer: a phase Ib study JW Moroney, J Powderly, CH Lieu, JC Bendell, SG Eckhardt, CW Chang, ... Clinical Cancer Research 26 (21), 5631-5637, 2020 | 36 | 2020 |
| The Chicago Consensus on peritoneal surface malignancies: management of ovarian neoplasms Annals of surgical oncology 27 (6), 1780-1787, 2020 | 32* | 2020 |
| A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: a GOG Foundation study BM Slomovitz, VL Filiaci, JL Walker, MC Taub, KA Finkelstein, ... Gynecologic oncology 164 (3), 481-491, 2022 | 27 | 2022 |
| An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): Cohort A of … J Liu, S Gaillard, AW Hendrickson, J Moroney, O Yeku, E Diver, ... Gynecologic Oncology 162, S17-S18, 2021 | 25 | 2021 |
| Phase I study of stereotactic body radiotherapy plus nivolumab and urelumab or cabiralizumab in advanced solid tumors CC Foster, GF Fleming, TG Karrison, CY Liao, AV Desai, JW Moroney, ... Clinical Cancer Research 27 (20), 5510-5518, 2021 | 24 | 2021 |
| Laparoscopy training in gynecologic oncology fellowship programs M Frumovitz, PT Soliman, M Greer, KM Schmeler, J Moroney, DC Bodurka, ... Gynecologic oncology 111 (2), 197-201, 2008 | 22 | 2008 |
